Jim Zarroli

Jim Zarroli is a business reporter for NPR News, based at NPR's New York bureau.

He covers economics and business news including fiscal policy, the Federal Reserve, the job market and taxes

Over the years, he's reported on recessions and booms, crashes and rallies, and a long string of tax dodgers, insider traders and Ponzi schemers. He's been heavily involved in the coverage of the European debt crisis and the bank bailouts in the United States.

Prior to moving into his current role, Zarroli served as a New York-based general assignment reporter for NPR News. While in this position he covered the United Nations during the first Gulf War. Zarroli added to NPR's coverage of the aftermath of Hurricane Katrina, the London transit bombings and the September 11, 2001 attacks on the World Trade Center.

Before joining the NPR in 1996, Zarroli worked for the Pittsburgh Press and wrote for various print publications.

Zarroli graduated from Pennsylvania State University.

Maurice "Hank" Greenberg, who built AIG into an insurance-industry powerhouse only to be forced out under pressure from regulators, must stand trial for accounting fraud, New York's highest court has ruled.

The New York Court of Appeals ruled that state officials can try to recover millions of dollars in bonuses and interest from Greenberg, 91, and his co-defendant, Howard Smith, 71, former AIG chief financial officer.

Copyright 2016 NPR. To see more, visit http://www.npr.org/.

Shareholders of Exxon Mobil and Chevron have voted to reject a series of resolutions aimed at encouraging the companies to take stronger actions to battle climate change.

But Exxon Mobil shareholders voted in favor of a rule that could make it easier for minority shareholders to nominate outsiders to the company's board, a potential victory for environmentalists.

Activist shareholders at both companies had placed an unusual number of resolutions on the ballot related to climate change.

Monsanto has rejected a $62 billion takeover bid from Bayer as "incomplete and financially inadequate," but left the door open to further negotiations with the German chemical and pharmaceutical giant.

Copyright 2016 NPR. To see more, visit http://www.npr.org/.

Pages